Background
Genomic imprinting is the epigenetic phenomenon by which alleles of select genes are differentially expressed according to the parent of origin [
1]. In humans, approximately 65 genes have been validated as imprinted [
2]. It has been suggested that imprinting is regulated primarily by DNA methylation of imprinting control regions (ICRs), which is established in the germ line and maintained throughout subsequent development [
3].
Loss of monoallelic expression at imprinted genes, known as loss of imprinting (LOI), has been associated with many cancer types including leukemia, colorectal, liver, and lung cancer [
4] and may play a role as an early driver in tumorigenesis [
5]. Abnormal methylation of imprinted genes can be detrimental given frequent roles in promoting and restricting cellular growth. For example, loss of methylation of the maternal allele of insulin-like growth factor-II (
IGF2) has been associated with increased expression of the growth-promoting gene in Wilms’ tumor [
6].
While studies have suggested a role for
IGF2 and tissue factor pathway inhibitor-2 (
TFPI2) LOI in prostate cancer [
7‐
9], the literature is restricted largely to these two genes. Here, we present a comprehensive investigation of methylation patterns at imprinted genes in prostate cancer. Our results indicate an overall dysregulation of imprinted gene methylation levels in prostate tumor tissue as compared to adjacent normal tissue, with pronounced gain of methylation at five tumor suppressor genes.
Discussion
This work represents the first comprehensive investigation of methylation changes in prostate cancer. Our results demonstrate an overall disruption of methylation at imprinted genes in prostate cancer tissue with a greater tendency toward hypermethylation than hypomethylation. Based on the magnitude and consistency of hypermethylation across multiple CpG sites, the strongest evidence for disrupted methylation patterns at imprinted genes was demonstrated at five tumor suppressor genes:
DLK1,
PLAGL1,
SLC22A18,
TP73, and
WT1. Of the five genes, LOI has been reported for
WT1 in Wilms’ tumor development, [
23] and has not been reported for the other four genes in the context of cancer development. Statistically significant hypermethylation across eight CpG sites in the
WT1 imprinting control region was confirmed using quantitative DNA methylation analysis (
P = 0.0104).
All five of the identified genes are presumed tumor suppressors and have been reported to play roles in cancer development.
DLK1, which encodes a transmembrane protein and is involved in cell differentiation, has been linked to liver cancer development and progression [
24,
25].
PLAGL1 is thought to be a transcriptional regulator and has been associated with pheochromocytoma, a tumor of the adrenal grand [
26].
SLC22A18 is a transporter of organic cations, and has been associated with glioma and breast cancer progression and survival [
27,
28].
WT1 plays an important role in normal development of the urogenital system, and is named after its association with Wilms’ tumor development [
29]. It has also been associated with breast cancer [
30], colorectal cancer [
31], and thyroid cancer [
32].
TP73 is an important member of the p53 family of cell cycle regulatory proteins, which is likely disrupted in the majority of cancers [
33,
34]. Under normal imprinting control,
DLK1,
PLAGL1, and
WT1 are paternally expressed, while
SLC22A18 and
TP73 are maternally expressed.
We hypothesized that the increased methylation observed would be associated with lower expression of these five genes, as previous research has established the role that DNA methylation plays in regulating gene expression [
35,
36]. Methylation impacts gene expression by altering chromatin structure and modifying interactions between proteins and DNA [
37]. Specifically, methylated promoter CpG islands attract methyl-CpG binding proteins and transcriptional repressors, thereby interfering with transcription factor binding and reducing transcription of the associated gene [
38,
39]. Accordingly, we queried the Oncomine database to determine if expression of identified genes significantly differed between prostate cancer and normal prostate tissue in publicly available datasets. Evidence was provided to support a tendency towards reduced expression in prostate tumor tissue at
DLK1,
PLAGL1,
SLC22A18, with less conclusive expression data for
WT1 and
TP73.
Taken together, our results suggest that observed promoter hypermethylation may be involved in the downregulation of these normally imprinted tumor suppressor genes, which may have important functional consequences for the development and progression of prostate cancer. For example, the transmembrane protein DLK1 has been shown to negatively regulate NOTCH1 [
40], which is overexpressed in prostate cancer and is associated with human prostate cancer cell invasion [
41]; this suggests that DLK1 downregulation may promote cell invasion via increased NOTCH1 expression. Loss of PLAGL1 expression has been associated with progression from benign to metastatic prostate tumors via the acquisition of androgen-independence, which enables prostate cancers to grow in the absence of androgens [
42]. Expression of SLC22A18 (also known as TSSC5) has been observed in adult human prostate tissue and may be involved in growth regulation and small molecule transport, including the export of potentially genotoxic substances [
43]; underexpression of this protein may consequently increase the risk of tumor formation. Finally, reduced expression of WT1 and TP73 proteins may have major implications for tumorigenesis: WT1 is a transcription factor that has been shown to regulate growth and induce apoptosis when overexpressed in prostate cancer cells [
44], and p73 is a p53-family protein that is key to apoptosis and growth arrest in human prostate cancer cells [
45].
Previous studies of loss of imprinting in prostate cancer have focused on
TFPI2 and
IGF2, with one study reporting lower methylation in the former [
8] and three studies providing inconsistent reports of methylation changes in the latter [
7,
9,
46]. No significant changes in methylation were identified in our data at
TFPI2 CpG sites, and
IGF2 methylation was higher at one CpG site and lower at the other four that were assessed. The resulting effects on expression of these two genes were variable across studies identified in the Oncomine expression database.
Conclusions
This study was limited by the inability to assess expression changes for our samples, as we were unable to extract sufficient RNA from our tissue samples to conduct qPCR analyses. It should also be noted that loss of imprinting has been previously observed in normal tissue from cancer patients [
47], which suggests that some differential methylation events at these genes would not be detectable in comparing tumor tissue to adjacent normal tissue. Despite these limitations, this study represents the first comprehensive assessment of methylation changes in prostate cancer. Our results suggest an overall tendency towards disruption of methylation at imprinted loci in prostate cancer tissue, and our data provide the first suggestion of disrupted imprinting patterns in cancer for four imprinted genes (
DLK1,
PLAGL1,
SLC22A18, and
TP73). Although our results need to be further confirmed by larger studies, these findings suggest a more widespread dysregulation of genomic imprinting in prostate cancer than previously reported. Future investigations such as studying the biological significance of dysregulated imprinting genes are also warranted.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DIJ analyzed the data and prepared the manuscript. YM and AF were involved in data analysis. WKK and YZ designed the study and were involved in data analysis, interpretation, and manuscript preparation. All authors read and approved the final manuscript.